Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease
Free accessOtherFirst published online March, 2008
Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease
Cyclooxygenase-2 inhibitors relieve pain from inflammatory conditions by decreasing the gastrointestinal side effects from traditional nonsteroidal anti-inflammatory drugs. Basic research provided plausible mechanisms and some observational epidemiological studies, case-control and cohort, indicated that patients prescribed with cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory drugs had increased risks for myocardial infarction and stroke. Because patients prescribed with cyclooxygenase-2 inhibitors were systematically different, uncontrolled and uncontrollable confounding by indication was as large as the observed risks. Thus, epidemiological studies or their meta-analyses could not discern whether, and if so, how much, the risks were real. A comprehensive meta-analysis of randomized trials indicated that cyclooxygenase-2 inhibitors increased the risk of vascular events by 42%, almost exclusively myocardial infarction, as did high-dose regimens of ibuprofen and diclofenac, but not naproxen. Individual clinical judgments and policy decisions should include cardiovascular disease and noncardiovascular disease risks including gastrointestinal side effects and clinical benefits including improved quality of life from less pain and disability.
Tanaka Y., Ward SL, Smith WL. Immunochemical and kinetic evidence for two different prostaglandin H-prostaglandin E isomerases in sheep vesicular gland microsomes. J Biol Chem. 1987;262:1374-1381.
2.
Hennekens CH, Buring JEEpidemiology in Medicine. Boston, MA: Little, Brown and Company; 1987.
3.
Gimeno V., Castellsague J., Maguire A., Pérez Gutthann S.Gastrointestinal and cardiovascular characterization of users of valdecoxib and other COX-2 specific inhibitors [abstract]. Pharmacoepidemiol Drug Saf.2004;13:S236.
4.
Wolfe F., Flowers N., Burke TA, Arguelles LM, Petitti D.Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol . 2002;29:1015-1022.
5.
McGettigan P. , Henry D.Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006 ;296:1633-1644.
6.
Graham DJCOX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA. 2006;296:1653-1656.
7.
Guidance for Clinical Trial Sponsors: On the establishment and operation of clinical trial data monitoring committees. FDA Web site . http://www.fda.gov/cber/guidelines.htm. Accessed on December 11, 2007.
8.
McAdam BF , Catella-Lawson F., Mardini IA, Kapoor S., Lawson JA, FitzGerald GASystemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96:272-277.
9.
Antman EM, DeMets D., Loscalzo J.Cyclooxygenase inhibition and cardiovascular risk. Circulation . 2005;112: 759-770.
10.
Catella-Lawson F., McAdam B., Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids . J Pharmacol Exp Ther.1999;289:735-741.
11.
Kawka DW, Ouellet M., Hetu P-O., Singer II, Riendeau D.Double-label expression studies of prostacyclin synthase, thromboxane synthase and COX isoforms in normal aortic endothelium. Biochim Biophys Acta. 2007;1771:45-54.
12.
Wong E., Huang JQ, Tagari P., Riendeau D.Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis. 2001;157:393-402.
13.
Tuleja E., Mejza F., Cmiel A., Szczeklik A.Effects of cyclooxygenase inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men. Arterioscler Thromb Vasc Biol. 2003;23:1111-1115.
14.
Preston FE, Whipps S., Jackson CA, French AJ, Wyld PJ, Stoddard CJInhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin . N Engl J Med. 1981; 304:76-79.
15.
Mason PJ, Jacobs AK, Freedman JEAspirin resistance and atherothrombotic disease. J Am Coll Cardiol.2005; 46:986-993.
16.
Ridker PM, Cushman M., Stampfer MJ, Tracy RP, Hennekens CHInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
17.
Burleigh ME , Babaev VR, Yancey PG, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoEdeficient and C57BL/6 mice. J Mol Cell Cardiol. 2005;39: 443-452.
18.
Monakier D. , Mates M., Klutstein MW, et al. Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. Chest2004;125:1610-1615.
19.
Bogaty P., Brophy JM, Noel M., et al. Impact of prolonged cyclososygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. Circulation. 2004;110:934-939.
20.
Title LM, Giddens K., MCInterney MM, McQueen MJ, Nassar BAEffect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol. 2003;42:1747-1753.
21.
Ray WA, Stein CM, Daugherty JR, Hall K., Arbogast PG, Griffin MRCOX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071-1073.
22.
Mamdani M., Rochon P., Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med.2003;163:481-486.
23.
Layton D., Heeley E., Hughes K., Shakir SAComparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford). 2003;42:1342-1353.
24.
Solomon DH, Schneeweiss S., Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004; 109:2068-2073.
25.
Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins CDSelective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med.2005;165:181-186.
26.
Kimmel SE, Berlin JA, Reilly M., et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med.2005;142: 157-164.
27.
Harrison-Woolrych M., Herbison P., McLean R., Ashton J., Slattery J.Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme. Drug Saf. 2005;28: 435-442.
28.
Graham DJ, Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective nonsteroidal anti-inflammatory drugs: nested case-control study. Lancet . 2005;365:475-481.
29.
Levesque LE , Brophy JM, Zhang B.The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med. 2005;142:481-489.
30.
Johnsen SP, Larsson H., Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005;165:978-984.
31.
Hippisley-Cox J., Coupland C.Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ . 2005;330:1366-1373.
32.
Sudbo J., Lee JJ, Lippman SM, et al. Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. Lancet. 2005;366:1359-1366.
33.
Bombardier C. , Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med.2000;343:1520-1528.
34.
US Food and Drug Administration.FDA issues Public Health Advisory recommending limited use of Cox-2 inhibitors: agency requires evaluation of prevention studies involving COX-2 selective agents . FDA Talk Paper, 2004. Available at http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01336.html. Accessed January 19, 2005.
35.
Smith EF, Lefer AMStabilization of cardiac lysosomal and cellular membranes in protection of ischemic myocardium due to coronary occlusion: efficacy of the nonsteroidal anti-inflammatory agent, naproxen. Am Heart J. 1981;101: 394-402.
36.
Van Hecken A., Schwartz JI, Depre M., et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol.2000;40:1109-1120.
37.
Capone ML, Tacconelli S., Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004;109:1468-1471.
38.
Brochier MLEvaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. Eur Heart J. 1993;14:951-957.
39.
Fornaro G., Rossi P., Mantica PG, et al. Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study. Circulation. 1993;87:162-164.
40.
Farkouh ME, Kirshner H., Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet . 2004;364:675-684.
41.
Bresalier RS , Sandler RS, Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med.2005; 352:1092-1102.
42.
Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med.2005;352: 1071-1080.
43.
Arber N., Eagle CJ, Spicak J., et al. Celecoxib for the prevention of colorectal adenomatous polyps . N Engl J Med.2006;355:885-895.
44.
Ott E., Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg.2003;125:1481-1492.
45.
Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison . Lancet. 2006;368:1771-1781.
46.
ADAPT Research Group ( 2006) Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) . PLoS Clin Trials. 2006;1:e33. doi:10.1371/journal.pctr.0010033.
47.
Mukherjee D. , Nissen SE, Topol EJRisk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959.
48.
Konstam MA, Weir MR, Reicin A., et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104:2280-2288.
49.
White WB, Faich G., Borer JS, Makuch RWCardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol. 2003;92:411-418.
50.
Kearney PM, Baigent C., Godwin J., Halls H., Emberson JR, Patrono C.Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials . BMJ. 2006;332:1302-1308.
51.
Zhang J., Ding EL, Song Y.Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006;296:1619-1632.
52.
Garcia Rodriguez LA, Hernandez-Diaz S.Nonsteroidal anti-inflammatory drugs as a trigger of clinical heart failure. Epidemiology . 2003;14:240-246.
53.
Antman E., Bennett JS, Daugherty A., Furberg C., Roberts H., Taubert KAUse of non-steroidal anti-inflammatory drugs: an update for clinicians. A scientific statement from the American Heart Association. Circulation. 2007;115:1-9.
